SK Group's Pharma companies make successive success
By Lee, Seok-Jun | translator Alice Kang
21.07.29 16:52:28
가나다라
0
Non-listed SK Plasma raises ₩110 billion as paid-in capital increase…participation from Korea Investment Partners etc.
SK Bioscience and SK Biopharmaceutical’s raises ₩1.4918 trillion and ₩959.3 billion at KOSPI IPO
Being able to invest in independent corporations differentiated according to business characteristics raised investment attraction
SK Group’s pharmaceutical companies have successively succeeded in raising large-scale funds. The analysis is that being able to invest in independent corporations differentiated by business characteristics attracted market investment.
SK Group’s pharmaceutical companies, which all use the SK name, are operated in different areas by SK or SK Discovery without mixed shares.
SK operates SK Biopharmaceuticals (new drug development) and SK Pharmteco (CMO). SK Discovery operates SK Chemical (pharmaceutical business), SK Plasma (blood products), and SK Bioscience (vaccines).
SK Plasma, a non-listed company, recently raised ₩110 billion through a third-par
Lee, Seok-Jun(wiviwivi@dailypharm.com)
If you want to see the full article, please JOIN US (click)